Koselugo® (selumetinib) – New orphan drug approval
April 10, 2020 - The FDA announced the approval of AstraZeneca and Merck’s Koselugo (selumetinib), for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Top